益生菌对严重脓毒症危重患儿细胞因子水平的影响:双盲、安慰剂对照试验
该研究为随机、双盲、安慰剂对照试验,在北印度一家三级教学医院ICU纳入3个月至12岁严重脓毒症患儿,随机分为益生菌组(n=50)和安慰剂组(n=50)。益生菌组接受VSL#3 1袋每日2次连用7天,安慰剂组接受麦芽糖和二氧化硅。主要终点为第1天至第7天细胞因子水平变化。第7天益生菌组促炎细胞因子(白细胞介素-6、白细胞介素-12p70、白细胞介素-17、肿瘤坏死因子-α)显著低于安慰剂组,抗炎细胞因子(白细胞介素-10、转化生长因子-β1)显著高于安慰剂组;第7天序贯器官衰竭评估评分益生菌组显著低于安慰剂组(1 vs 3)。医疗保健相关感染发生率(14% vs 20%)和ICU停留时间(6.5 vs 9天)在益生菌组有降低趋势但未达统计学显著,两组死亡率相似。
要点
- 第7天益生菌组促炎细胞因子显著低于安慰剂组:白细胞介素-6 80 vs 186 pg/mL(p=0.001),白细胞介素-12p70 44 vs 79 pg/mL(p=0.001),白细胞介素-17 217 vs 293 pg/mL(p=0.01),肿瘤坏死因子-α 192 vs 348 pg/mL(p=0.01)。
- 第7天益生菌组抗炎细胞因子显著高于安慰剂组:白细胞介素-10 320 vs 240 pg/mL(p=0.02),转化生长因子-β1 311 vs 221 ng/mL(p=0.01)。
- 第7天序贯器官衰竭评估评分益生菌组显著低于安慰剂组(1 vs 3)。
- 医疗保健相关感染发生率(14% vs 20%)和ICU停留时间(6.5 vs 9天)在益生菌组呈降低趋势但未达统计学显著,两组死亡率相似。
- 益生菌组从第1天至第7天促炎细胞因子显著下降、抗炎细胞因子显著上升,安慰剂组无此变化。
适用人群与场景
- 3个月至12岁严重脓毒症患儿,收治于北印度一家三级教学医院ICU。
处置流程与药物剂量
- 益生菌组:VSL#3(Danisco-Dupont USA,Madison,WI;含副干酪乳杆菌、植物乳杆菌、嗜酸乳杆菌、德氏乳杆菌、长双歧杆菌、婴儿双歧杆菌、短双歧杆菌、唾液链球菌;麦芽糖和二氧化硅),1袋每日2次,连用7天。
- 安慰剂组:麦芽糖和二氧化硅。
- 第1天和第7天采血检测白细胞介素-6、白细胞介素-12p70、白细胞介素-17、肿瘤坏死因子-α、白细胞介素-10和转化生长因子-β1。
研究设计与关键结果
- 研究类型:随机、双盲、安慰剂对照试验;人群:3个月至12岁严重脓毒症患儿;干预:VSL#3 1袋每日2次连用7天 vs 安慰剂(麦芽糖和二氧化硅);主要终点:第1天至第7天细胞因子水平变化。
- 第7天益生菌组促炎细胞因子显著低于安慰剂组:白细胞介素-6 80 vs 186 pg/mL(p=0.001),白细胞介素-12p70 44 vs 79 pg/mL(p=0.001),白细胞介素-17 217 vs 293 pg/mL(p=0.01),肿瘤坏死因子-α 192 vs 348 pg/mL(p=0.01)。
- 第7天益生菌组抗炎细胞因子显著高于安慰剂组:白细胞介素-10 320 vs 240 pg/mL(p=0.02),转化生长因子-β1 311 vs 221 ng/mL(p=0.01)。
- 从第1天至第7天,益生菌组促炎细胞因子显著下降:白细胞介素-6 196→80 pg/mL(p=0.001),白细胞介素-12p70 71→44 pg/mL(p=0.01),白细胞介素-17 258→217 pg/mL(p=0.01),肿瘤坏死因子-α 347→192 pg/mL(p=0.001);抗炎细胞因子显著上升:白细胞介素-10 198→320 pg/mL(p=0.001),转化生长因子-β1 216→311 ng/mL(p=0.001)。
- 第7天序贯器官衰竭评估评分益生菌组显著低于安慰剂组(1 vs 3)。
- 医疗保健相关感染发生率益生菌组14% vs 安慰剂组20%,ICU停留时间益生菌组6.5天 vs 安慰剂组9天,均为非显著趋势;两组死亡率相似。
证据类型、等级与局限
- 证据类型:随机、双盲、安慰剂对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在严重脓毒症患儿中,补充VSL#3 1袋每日2次连用7天可显著降低促炎细胞因子并升高抗炎细胞因子水平,第7天序贯器官衰竭评估评分更低(1 vs 3)。
- 医疗保健相关感染发生率和ICU停留时间的降低趋势未达统计学显著,死亡率两组相似。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the effect of probiotics on cytokines in children with severe sepsis.
DESIGN: Randomized, double-blind, placebo-controlled trial.
SETTING: ICU of a tertiary care teaching hospital in North India.
PATIENTS: Children 3 months to 12 years old with severe sepsis.
INTERVENTIONS: Enrolled children were randomized to probiotic (n = 50) and placebo (n = 50) groups. Probiotic group received VSL#3 (Danisco-Dupont USA, Madison, WI) (Lactobacillus paracasei, L. plantarum, L. acidophilus, L. delbrueckii, Bifidobacterium longum, B. infantis, B. breve, Streptococcus salivarius; maltose and silicon dioxide), and placebo group received maltose and silicon dioxide. Dose was 1 sachet twice daily for 7 days. Blood was collected on days 1 and 7 for estimation of interleukin-6, interleukin-12p70, interleukin-17, tumor necrosis factor-α, interleukin-10, and transforming growth factor -β1. "Primary outcome": Change in cytokine levels in probiotic and placebo groups from day 1 to 7. "Secondary outcomes": Sequential Organ Failure Assessment score, healthcare-associated infections, ICU stay, and mortality.
MEASUREMENTS AND MAIN RESULTS: On day 7, probiotic group had significantly lower levels of proinflammatory cytokines (interleukin-6 [80 vs 186 pg/mL, p = 0.001]; interleukin-12p70 [44 vs 79 pg/mL, p = 0.001]; interleukin-17 [217 vs 293 pg/mL, p = 0.01]; and tumor necrosis factor-α [192 vs 348 pg/mL, p = 0.01]) and higher levels of antiinflammatory cytokines (interleukin-10 [320 vs 240 pg/mL, p = 0.02] and transforming growth factor-β1 [311 vs 221 ng/mL, p = 0.01]) than placebo group. From day 1 to 7, probiotic group showed significant decrease in proinflammatory cytokines (interleukin-6 [196-80 pg/mL, p = 0.001]; interleukin-12p70 [71-44 pg/mL, p = 0.01]; interleukin-17 [258-217 pg/mL, p = 0.01]; and tumor necrosis factor-α [347-192 pg/mL, p = 0.001]) and increase in antiinflammatory cytokines (interleukin-10 [198-320 pg/mL, p = 0.001] and transforming growth factor-β1 [216-311 ng/mL, p = 0.001]) as compared to placebo group. Sequential Organ Failure Assessment score on day 7 was significantly less in probiotic group (1 vs 3). There was a nonsignificant trend toward lower incidence of healthcare-associated infections (14% vs 20%) and duration of ICU stay (6.5 vs 9 d) in probiotic group. Mortality was similar in two groups.
CONCLUSIONS: Probiotics supplementation for 7 days resulted in significant decrease in proinflammatory and increase in antiinflammatory cytokines in children with severe sepsis.
参考来源
- Angurana SK, Bansal A, Singhi S, et al. Evaluation of Effect of Probiotics on Cytokine Levels in Critically Ill Children With Severe Sepsis: A Double-Blind, Placebo-Controlled Trial. Crit Care Med. 2018. PMID: 29957709. doi:10.1097/CCM.0000000000003279
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。